NATIXIS - 2018 Registration document and annual financial report

5 FINANCIAL DATA

Consolidated financial statements and notes

Equity instruments at fair value through other comprehensive income 8.4.2

31/12/2018

Dividends recognized over the period

Derecognition over the period

Equity instruments derecognized during the period

Cumulative profit or loss on date of sale

Equity instruments held at 31/12/2018

Fair value on date of sale

Fair value

(in millions of euros)

Investments in unlisted and unconsolidated companies (a)

126

2 0

0 0

12

(4)

Other equity instruments

0

0

0

TOTAL (4) The total amount of changes in fair value reclassified as “Retained earnings” over the period that was related to disposals was -€4 million for (a) fiscal year 2018. 126 2 0 12

AVAILABLE-FOR-SALE FINANCIAL ASSETS AT DECEMBER 31, 2017 R

31/12/2017

(in millions of euros) Loans outstanding

18 18

Loans and receivables a

Accrued interest a

0

Securities

58,382 49,209

Fixed-income a

Variable income (b)

8,625

a

Accrued interest a

549

Total available-for-sale financial assets before impairment

58,400

Impairment of available-for-sale assets

(515)

Loans and receivables a Fixed-income securities a Variable income securities (c) a

(15) (43)

(458)

TOTAL (a)

57,885

Of which €44,444 million for insurance activities at December 31, 2017. (a) Including mutual fund units. (b)

In 2017, the permanent impairment of variable-income securities stood at €27 million. This relates to insurance portfolios for €15 million, the (c) impact of which was neutralized by a respective 89% given the profit-sharing mechanism. The 2017 expense can be broken down into additional impairment on securities previously impaired for €18 million, including €7 million for insurance portfolios and an allowance of €9 million for newly impaired securities in accordance with the application of analysis criteria, as defined in the accounting principles and methods, primarily applicable to insurance portfolios.

312

Natixis Registration Document 2018